Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Castellsagué, Xavier; Ault, Kevin A.; Bosch, F. Xavier; Brown, Darron R.; Cuzick, Jack; Ferris, Daron G.; Joura, Elmar A.; Garland, Suzanne M.; Giuliano, Anna R.; Hernández-Ávila, Mauricio; Huh, Warner K.; Iversen, Ole Erik; Kjær, Susanne K.; Luna, Joaquín; Monsonégo, Joseph; Muñóz, Núbia; Myers, Evan R.; Paavonen, Jorma; Pitisuttihum, Punnee; Steben, Marc; Wheeler, Cosette M.; Pérez, Gonzalo; Saah, Alfred J.; Luxembourg, Alain; Sings, Heather L.; Velicer, Christine

doi:10.1016/j.pvr.2016.03.002

Cited by 31 publications

(35 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although HPV 16 was the most prevalent genotype among patients with cervical disease, other HR‐HPV genotypes targeted by the nonavalent HPV vaccine were also detected in many patients with CIN2, CIN3, and ICC. Indeed, HR‐HPV genotypes 31, 33, 45, 52, and 58 were detected in 34.3% of CIN2, 33.3% of CIN3, and 19.4% of ICC occurrences; these rates were similar to those observed in other studies . The high proportion of ICC and CIN2/3 with HPV 16, 18, 31, 33, 45, 52, or 58 in Portugal appeared to be related to the high prevalence of HPV 31, 33, and 58.…”

Section: Discussionsupporting

confidence: 85%

“…Worldwide, approximately 90% of cervical cancers are attributed to HPV genotypes 16, 18, 31, 33, 45, 52, or 58 . Moreover, HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 are associated with 78% and 91% of CIN2 and CIN3 occurrences, respectively . In Europe, HPV 16 and 18 account for approximately 72.8% of all cervical cancers and 45.5% of high‐grade cervical dysplasia, whereas HPV genotypes targeted by the nonavalent vaccine account for 89% of cervical cancers and 82.3% of high‐grade cervical lesions .…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 are associated with 78% and 91% of CIN2 and CIN3 occurrences, respectively . In Europe, HPV 16 and 18 account for approximately 72.8% of all cervical cancers and 45.5% of high‐grade cervical dysplasia, whereas HPV genotypes targeted by the nonavalent vaccine account for 89% of cervical cancers and 82.3% of high‐grade cervical lesions . In Portugal, HPV 16 and 18 have been identified as accounting for 54.4% of CIN2, 62.9% of CIN3, and 77.4% of ICC based on CLEOPATRE II study data, and the present analysis demonstrated that HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for 89.3%, 97.1%, and 96.8%, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Potential impact of nonavalent HPV vaccine in the prevention of high‐grade cervical lesions and cervical cancer in Portugal

Pista¹,

Oliveira²,

Lopes³

et al. 2017

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential impact of nonavalent HPV vaccine in the prevention of high‐grade cervical lesions and cervical cancer in Portugal

Pista¹,

Oliveira²,

Lopes³

et al. 2017

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…The two largest prior studies, with 96 and 61 cases, were conducted in the Netherlands; these identified HPV16/18 in 79 and 94% of AIS cases (41 and 34% HPV16, 43 and 66% HPV18) . Four additional studies conducted in a variety of settings, with <50 cases each, also found HPV16/18 in the vast majority of AIS cases (ranging from 85% to 96%, with 51–71% HPV16 and 36–39% HPV18) …”

Section: Discussionmentioning

confidence: 99%

“…Similarly, reports indicate that the HPV types identified in CIN and AIS differ. While HPV16 is the most common type in both AIS and CIN lesions, data from several small studies found HPV18 more frequently in AIS than CIN lesions …”

Section: Introductionmentioning

confidence: 98%

Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015

Cleveland

Gargano

Park

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Primary prevention through the use of human papillomavirus (HPV) vaccination is expected to impact both cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS). While CIN is well described, less is known about the epidemiology of AIS, a rare cervical precancer. We identified AIS and CIN grade 3 (CIN3) cases through population‐based surveillance, and analyzed data on HPV types and incidence trends overall, and among women screened for cervical cancer. From 2008 to 2015, 470 AIS and 6,587 CIN3 cases were identified. The median age of women with AIS was older than those with CIN3 (35 vs. 31 years; p < 0.01). HPV16 was the most frequently detected type in both AIS and CIN3 (57% in AIS; 58% in CIN3), whereas HPV18 was the second most common type in AIS and less common in CIN3 (38% vs. 5%; p < 0.01). AIS lesions were more likely than CIN3 lesions to be positive for high‐risk types targeted by the bivalent and quadrivalent vaccines (HPV16/18, 92% vs. 63%; p < 0.01), and 9‐valent vaccine (HPV16/18/31/33/45/52/58, 95% vs. 87%; p < 0.01). AIS incidence rates decreased significantly in the 21–24 year age group (annual percent change [APC] overall: −22.1%, 95% CI: −33.9 to −8.2; APC among screened: −16.1%, 95% CI: −28.8 to −1.2), but did not decrease significantly in any older age group. This report on the largest number of genotyped AIS cases to date suggests an important opportunity for vaccine prevention of AIS, and is the first to document a decline in AIS incidence rates among young women during the vaccine era.

show abstract

Follow‐up with histopathology and HPV testing on LSIL cytology in China’s largest academic woman’s hospital

Tao

Zhang

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

Background Cervical cancer remains a major health problem in China. To provide baseline data for establishing the appropriate screening strategy, the authors investigated the histopathologic follow‐up and human papillomavirus (HPV) testing results of low‐grade squamous intraepithelial lesion (LSIL) cytology in the Chinese Largest Women Hospital. Methods Women with LSIL cytology, human papillomavirus (HPV) testing, and immediate histopathologic follow‐up between 2011 and 2016 were analyzed. Results The frequency of LSIL among 1,095,022 Papanicolaou (Pap) tests was 1.4%, and was significantly higher in cases using liquid‐based cytology (LBC; 1.5%‐1.6%) compared with conventional Pap smears (CPS; 0.5%). The CPS method had performance for predicting cervical intraepithelial neoplasia (CIN) that was comparable to that of LBC (75% vs 69.1% and 71.9%). Among 8079 LSIL cases with an immediate histopathologic diagnosis, CIN‐2/3 or higher (CIN‐2/3+) was found in 11.9% of cases and carcinoma in 0.3% of cases. A total of 158 patients (15.7%) with HPV‐positive LSIL had a diagnosis of CIN‐2/3 compared with 18 patients (5.5%) with HPV‐negative LSIL. In postmenopausal women with LSIL cytology, the detection rate for CIN‐2/3 in HPV‐negative patients was significant lower than that in HPV‐positive patients. Furthermore, HPV type 16 (HPV‐16) was the most common genotype noted in patients with CIN‐2+ lesions, whereas HPV‐18 was the most common in patients with CIN‐1. Conclusions Although its reporting rate is lower than that of LBC, CPS is useful due to its low cost and comparable predictive value. HPV testing is helpful for stratifying postmenopausal women with LSIL into lower and higher risk groups. HPV‐16 is the most commonly identified genotype in CIN‐2+ lesions diagnosed in Chinese women with LSIL cytology, whereas HPV‐18 is the most commonly identified genotype in patients with CIN‐1 lesions.

show abstract

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Cited by 31 publications

References 27 publications

Potential impact of nonavalent HPV vaccine in the prevention of high‐grade cervical lesions and cervical cancer in Portugal

Potential impact of nonavalent HPV vaccine in the prevention of high‐grade cervical lesions and cervical cancer in Portugal

Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015

Follow‐up with histopathology and HPV testing on LSIL cytology in China’s largest academic woman’s hospital

Contact Info

Product

Resources

About